Coronary diseaseLesion typeTotal occlusions

SOLACI-SOCIME 2018 | Justification of PCI for Coronary Chronic Total Occlusion

solaci
solaci
475
0

Read articles on the main presentations of the first day of SOLACI-SOCIME 2018 Congress.

See the presentation by Dr. Jaikirshan Khatri, entitled “Justification of PCI for Coronary Chronic Total Occlusion”.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Previous article
SOLACI-SOCIME 2018 | TAVI in a low risk patients
Next article
SOLACI-SOCIME 2018 | Acceso Vascular por Vía Radial. Slender Devices
solaci
solaci

More articles by this author

Drugs for the Treatment of No-Reflow During PCI

Dr. Omar Tupayachi - 0
The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Dr. Omar Tupayachi - 0
Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

Dr. Omar Tupayachi - 0
In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

Dr. Omar Tupayachi - 0
The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Acute coronary syndromes

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in...
Dr. Omar Tupayachi -
SOLACI Sessionsspot_img

Recent Articles

Drugs for the Treatment of No-Reflow During PCI

Dr. Omar Tupayachi - 0
The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Coronary revascularization before TAVI: prior PCI or conservative management?

Dr. Juan Manuel Pérez - 0
The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Dr. Omar Tupayachi - 0
Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...